ADMS / Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus

Adamas One Corp. JEWL, said it priced 2.45 million shares at $4.50 a share for proceeds of $11 million in its initial public offering for trading on F more_horizontal

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio more_horizontal

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio more_horizontal

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio more_horizontal

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS more_horizontal

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS more_horizontal

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS more_horizontal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NAS more_horizontal